CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

The Trump administration says it will not move forward with a Biden proposal that Medicare cover anti-obesity drugs such as Novo Nordisk’s Wegovy and Zepbound from Eli Lilly. The drugs have been shown ...

December 24, 2025) - The Obesity Medicine Association (OMA) released its Position Statement on Medicare and Medicaid Coverage and Expanded Access to Obesity Medications, detailing the association's ...

Thirteen states cover GLP-1 drugs through their Medicaid programs, and others are considering following suit (Mario Tama/Getty Images). President Donald Trump and Health Secretary Robert F. Kennedy Jr ...

The post Older Americans Quit Weight-Loss Drugs in Droves appeared first on Katie Couric Media.

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move.

President Trump has successfully negotiated a groundbreaking deal to include obesity drugs under Medicare coverage, marking a significant shift in healthcare policy. This agreement, announced on ...

At least 12% of adults in the U.S. have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, but ...

The Biden administration proposed a new rule Tuesday that would allow anti-obesity drugs like Wegovy and Zepbound to be covered under Medicaid and Medicare for more Americans. Millions of Americans ...

Medicare covers treatments such as nutritional counseling and weight loss surgeries under certain conditions but not general weight loss programs or obesity medications. However, Medicare may expand ...

The White House recently announced a landmark deal with pharmaceutical companies Eli Lilly and Nordisk that will impact Medicare beneficiaries and others in the coming months. The agreement cuts ...